1. Technical Field
The present disclosure relates to systems and methods that measure fast decaying T2* relaxation for effective quantification of labeled cells using magnetic resonance imaging. The disclosed systems and methods are useful in a variety of applications, including cell trafficking and cell therapy.
2. Background Art
Cellular therapies using stem cells and immune cells for the purpose of repair and revascularization are being increasingly applied in clinical trials. Accurate delivery of cells to target organs can make the difference between failure and success. Quantifying the number of cells delivered in target tissue(s) is of great importance to optimize dose and timing of cellular therapy. Superparamagnetic iron oxide (SPIO) agents have been used to label cells ex vivo, providing researchers with the ability to monitor the migration, proliferation and homing of these cells with magnetic resonance (MR) imaging. SPIO labeling causes a strong relaxation rate (R2) effect that increases linearly with iron concentration. R2* is defined as 1/T2*.
T2* relaxometry is usually achieved by multiple gradient echo imaging. In tissues containing highly concentrated iron labeled cells, T2* can be ultrashort. In exemplary instances, T2* is below 1 to 2 milliseconds, although precise T2* periods vary from application-to-application. The echo time of gradient echo is generally limited by hardware settings. It is not trivial to achieve ultrashort echo time in practical settings. Therefore, the signal decay in tissues with ultrashort T2* is generally too rapid for regular gradient echo imaging.
Despite efforts to date, a need remains for systems and/or methods that overcome difficulties and limitations associated with conventional cell quantification techniques. In addition, a need remains for cell quantification techniques that do not require hardware modification(s) and/or dedicated RF pulse designs. Still further, systems and methods are needed for effectively and reliably monitoring and/or quantifying labeled cell levels, e.g., labeled stem cells, in various applications, including cellular therapies and the like. These and other needs are satisfied by the systems and methods disclosed.
The present disclosure provides systems and methods for measuring and/or quantifying cell levels in various applications, e.g., cell trafficking and cell therapy. Exemplary embodiments of the disclosed systems and methods involve the use of cells that have been labeled ex vivo with a contrasting agent or other identifying characteristic. The labeled cells are monitored using MR imaging so as to assess the migration, proliferation and/or homing of the labeled cells. Typically, the contrasting agent is SPIO, although alternative contrasting agents may be employed without departing from the spirit or scope of the present disclosure.
According to the present disclosure, T2* relaxometry is advantageously employed in measuring labeled cell concentrations in a variety of cell-related applications. Since T2* is ultrashort in highly concentrated iron labeled cells, advantageous systems and methods for measuring T2* relaxometry are disclosed herein, such systems and methods using a sequence of spin echo imaging rather than the standard gradient echo imaging to achieve desirable results. In exemplary instances, T2 is below 1 to 2 milliseconds, although the disclosed systems and methods have advantageous application across a broad range of T2* values, such T2* values generally varying from application-to-application. The disclosed systems and methods induce a regular spin echo signal generating a first spin echo image, followed by inducing multiple spin echo signals generating a series of additional spin echo images from suitable echo shifts towards said T2* decay, and then deriving T2*maps using exponential fitting.
Spin echo signals exiting the cells for MR imaging are formed by a first radio frequency (RF) pulse followed by a second RF pulse, respectively. Using spin echo signals, a T2 curve is generated wherein T2 is much longer for cells labeled with SPIO particles/nanoparticles than T2* and defined by Msse−t/T. The T2* decay curve of the spin echo is then defined by MsseTE/T2e−(t−TE)/T2*. The multiple spin echo images are taken at different intervals defined by an echo shift step that could be less than 1 ms. An ultrashort T2* map is generated by the first spin echo image and the multiple spin echo images with suitable echo shifts by exponential fitting. An overall T2* map is generated by overlying the ultrashort T2* map on a regular T2 map.
Additional features, functions and benefits of the disclosed systems and methods will be apparent from the description which follows, particularly when read in conjunction with the appended figures.
To assist those of ordinary skill in the art in making and using the disclosed systems and methods, reference is made to the appended figures, wherein:
a is an axial gradient echo image of a tumor rat;
b is an axial spin echo image with an echo shift of 0.8 ms;
c is a plussian blue strained tumor slice;
a is a regular T2* map masked by a signal threshold to remove noise;
b is an ultrashort T2 map overlaid on a regular T2 map;
a is representative R2* maps of labeled flank tumors;
b is representative R2* maps of unlabeled flank tumors;
a)-6(c) are histograms of tumors with different number of iron labeled cells; and
Systems and methods are disclosed for measuring and/or quantifying cell levels, without the need for hardware modifications and/or dedicated RF pulse designs. The disclosed systems/methods have wide ranging utility, including cell trafficking and cell therapy applications. Labeled cells are monitored using MR imaging so as to assess the migration, proliferation and/or homing thereof. Fast decaying T2* relaxation times are measured using MR imaging so as to effectively quantify the labeled cells, as described herein.
SPIO agents influence the T1, T2 and T2* relaxation time. For cellular compartmental SPIO, the effect on T2* relaxation is ten times higher than on T2 relaxation. As a result, T2 is much longer than T2* in SPIO-labeled cells. The disclosed systems and methods utilize the relatively long T2 decay by acquiring a series of spin echo images to advantageously facilitate a determination of the T2* value, despite the massive signal loss associated with the ultrashort T2* decay.
The signal acquired at the gradient echo is defined by Msse−TE/T2*, where Mss is the magnetization at steady state. In tissues with highly concentrated iron labeled cells, T2* could be below 1 or 2 milliseconds. Therefore, the signal can decay to a noise level with an echo time of a couple milliseconds. Prior efforts to reduce the TE have involved the modification of the hardware or large amount of work on the sequence design, neither approach being optimal and/or practical for many conventional applications.
Measurement of ultrashort T2* relaxation can be achieved by acquiring a series of spin echo images as shown in
With further reference to
To further illustrate the uses and advantages associate with the disclosed systems and methods, reference is made to the following examples. However, it is to be understood that such examples are not limiting with respect to the scope of the present disclosure, but are merely illustrative of exemplary implementations and/or utilities thereof:
To facilitate measurement of fast decaying T2* relaxation in tissues containing highly concentrated iron labeled cells, where T2* decay is too rapid for regular multiple gradient echo T2* mapping, the following methodology was employed. In vivo MR experiments in rats with iron labeled tumors were used to demonstrate that the disclosed methodology can be used to quantify ultrashort T2* down to 1 to 2 milliseconds or less. Combined with regular T2* mapping, the disclosed technique may be used to improve in vivo quantification and monitoring of tissues containing heavily iron labeled cells.
SPIO nanoparticles are widely used to influence the T1, T2 and T2* relaxation times of labeled cells and tissues. The T2* relaxation time is the most sensitive parameter to detect SPIO-labeled cells and, based on the advantageous systems and methods disclosed herein, T2* relaxometry can be effectively employed in the quantification and monitoring of labeled stem cells in cellular therapies. As noted above, T2* relaxometry is generally performed by multiple gradient echo imaging. However, in tissues containing highly concentrated iron labeled cells, T2* can be below 2 milliseconds and therefore the signal decay is too rapid for regular gradient echo times. Taking advantage of the relatively long T2 decay of cell bounded SPIO, the disclosed system/method is employed to measure fast decaying T2* relaxation using a series of spin echo images. In this illustrative example, the in vivo quantification of short T2* in rats with iron labeled tumors was investigated.
Sequence Development: Measurement of ultrashort T2* was achieved by acquiring a series of spin echo images as shown in
In vivo experiment: C8161 melanoma cells were labeled with Feridex-protamine sulfate (FEPro) complexes using procedures labeling procedures as are known in the art. 2×106 FEPro labeled or unlabeled (control) melanoma cells were implanted subcutaneously bilaterally into the flanks of 5 nude rats. MRI was performed approximately two weeks after the inoculation of tumor cells on a 3 T Intera whole-body scanner (Philips Medical System) using a dedicated 7 cm rat solenoid RF-coil. A regular T2* map was acquired with multiple gradient echo sequence (MGES) [TR/TE=1540/16 ms, 13 echoes, 256×256 matrix, 17 slices, Slice-thickness=1.0 mm, FOV=80 mm, NEX=4]. To measure the short T2*, five sets of spin echo images were obtained with the readout echo shifted 0 ms, 0.4 ms, 0.8 ms, 1.2 ms and 2.3 ms, respectively, with the following parameters: TR/TE=1000/6.4, 144×144 matrix, 17 slices, Slice-thickness=1.5 mm, FOV=80 mm, NEX=4.
Data analysis: Data analysis was performed using an IDL software tool. T2 maps were derived using exponential fitting. Both datasets (i.e., regular T2* map and the short T2* map) were combined and displayed as T2* map.
Ultrashort T2* relaxometry maps and MGES conventional T2* maps were obtained for 4 rats.
Conclusion: This experiment demonstrated the effective measurement of ultrashort T2* relaxation times in cells and tissues. In vivo MR experiments demonstrate that this method can measure ultrashort T2* values down to 1 ms or less in highly concentrated iron labeled cells. Combined with the conventional T2* map, the disclosed technique can be employed to improve the in vivo quantification and monitoring of tissues containing heavily iron labeled cells.
Quantifying the number of labeled stem cells in target tissues in experimental models is of great importance to optimize dose and timing of cellular therapy in clinical trials. SPIO agents are used to label cells to monitor their migration, proliferation and/or homing by MR imaging. R2*(1/T2*) relaxation rate is a sensitive parameter for quantitative detection of intracellular SPIO.
In this illustrative example, the quantitative relationship between the number of iron labeled cells and R2* relaxation rate in a tumor rat model was investigated. More particularly, the quantitative relationship between iron labeled cells and tissue R2* relaxation rate in a tumor rat model was investigated. The in vivo experiments demonstrated an excellent linear correlation between the number of iron labeled cells and tissue R2. The data further illustrates that R2 measurement is a reliable and sensitive approach for the in vivo quantification of iron labeled cells.
C8161 melanoma cells and C6 glioma cells were labeled with Feridex-protamine sulfate (FEPro) complexes using known procedures. Nude rats were implanted subcutaneously bilaterally with 2×106 FEPro labeled and unlabeled (control) melanoma cells (n=4) or 1×106 FEPro labeled and unlabeled C6 glioma cells (n=4). MRI was performed approximately two weeks after the inoculation of the tumor cells on a 3 T Intera whole-body scanner (Philips Medical System) using a dedicated 7 cm rat solenoid RF-coil. A regular R2* map was acquired with multiple gradient echo sequence [TR/TE=1540/16 ms, 13 echoes, 256×256 matrix, 17 slices, Slice-thickness=1.0 mm, FOV=80 mm, NEX=4]. To measure the R2* relaxation in tissues with highly concentrated labeled cells, five sets of spin echo images were obtained with the readout echo shifted 0 ms, 0.4 ms, 0.8 ms, 1.2 ms and 2.3 ms respectively [TR/TE=1000/6.4, 144×144 matrix, 17 slices, Slice-thickness=1.5 mm, FOV=80 mm, NEX=4]. R2* relaxation rates were calculated by exponential fitting using an IDL software tool. Both datasets (i.e., regular R2* map and R2* map of tissues with highly concentrated labeled cells) were combined. The R2* relaxation of the tumor was calculated as the average of pixel-wised R2* relaxation over the whole tumor volume. The number of labeled cells per mm3 was determined as the number of implanted tumor cells divided by the tumor volume.
Results: Iron labeling did not change the tumor's growth. There was no significant statistical difference in tumor size between labeled and unlabeled tumors. Labeled tumor sizes ranged from 1890 mm3 to 4950 mm3 at the time of imaging, which translates to 325 to 1056 labeled cells per mm3 in eight tumors.
FEPro labeling significantly lengthened the R2* relaxation rate of the tumor.
Conclusion: In this illustrative example, the quantitative relationship between the iron labeled cells and tissue R2* relaxation rate was investigated. Although two different tumor cell lines were used, the in vivo data demonstrated an excellent linear correlation between the number of iron labeled cells and tissue R2*. The experimental data further illustrated that R2 measurement is a reliable and sensitive tool for quantification of iron labeled cells. Accordingly, the disclosed systems and methods may be employed for effective quantitative non-invasive assessment of iron labeled cells in vivo.
In sum, the systems and methods of the present disclosure offer significantly enhanced techniques for MR measurement of labeled cells in a variety of applications. Indeed, current investigations in cell trafficking and therapy begin with the injection of large amounts of SPIO labeled cells into a specific site, resulting in very short T2* in the labeled and surrounding tissues. The disclosed systems and methods facilitate significant improvements in the quantification of labeled cells, despite the ultrashort T2* decay to be encountered in such tissue systems. The disclosed systems and methods can also be applied to measure ultrashort T2* of other contrast agents that cause significant difference in T2 and T2* relaxation.
Although the present disclosure has been described with reference to exemplary embodiments and implementations thereof, the disclosed systems and methods are not limited to such exemplary embodiments/implementations. Rather, as will be readily apparent to persons skilled in the art from the description provided herein, the disclosed systems and methods are susceptible to modifications, alterations and enhancements without departing from the spirit or scope of the present disclosure. Accordingly, the present disclosure expressly encompasses such modification, alterations and enhancements within the scope hereof.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/IB07/51013 | 3/22/2007 | WO | 00 | 9/30/2008 |
Number | Date | Country | |
---|---|---|---|
60788473 | Mar 2006 | US |